NASD · Healthcare · Drug Manufacturers - General · USA
Biogen Inc is a large cap company (market value between $10 billion and $200 billion) in the Drug Manufacturers - General industry.
Biogen is a global biopharmaceutical company that discovers, develops and delivers therapies for serious and complex diseases. The company offers medicines to treat multiple sclerosis, spinal muscular atrophy, Friedreich's ataxia and amyotrophic lateral sclerosis, and collaborates on treatments for Alzheimer's disease and postpartum depression. Biogen also commercializes biosimilars.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Biogen Inc stock.
Overvalued: intrinsic value $145.77 per share, market price $233.48, margin of safety -60.2% (as of 2026-10-19).
Discounting its cash flows at 9.2% (average of 3 methods) values the shares at $145.77; the price of $233.48 is 60% above that value, and 74% of that value comes from beyond year five.
Leak Score: 51/100 on 11 of 12 signals (Weak Signal).
17 more funds hold it; the full list is part of the paid plan.
All 21 Drug Manufacturers - General stocks
6 more in this industry show a wider margin of safety.
BIIB is overvalued (as of the 2026-10-19 close). Discounting its cash flows at 9.2% (average of 3 methods) values the shares at $145.77; the price of $233.48 is 60% above that value, and 74% of that value comes from beyond year five.
$145.77 per share (as of the 2026-10-19 close), against a market price of $233.48. That is a margin of safety of -60.2%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
51 out of 100, which we rate "Weak Signal", on 11 of 12 value investing signals.